Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study
Background: Medications can increase the incidence rate of metabolic syndrome (MetS) and insulin resistance (IR). This study aimed to evaluate the effects of Carbamazepine (CBZ) or Valproate (VPA) as monotherapy on the development of MetS and IR in adult Iranian epileptic patients.Methods: In this o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kerman University of Medical Sciences
2021-11-01
|
| Series: | Journal of Kerman University of Medical Sciences |
| Subjects: | |
| Online Access: | https://jkmu.kmu.ac.ir/article_91826_97358370ed05cb71b3acd1e6f8140296.pdf |
| _version_ | 1797790797479804928 |
|---|---|
| author | Mahnaz Bayat Nasrin Jalali Maryam Poursadeghfard Mohammad Hossein Dabbaghmanesh Nahid Ashjazadeh |
| author_facet | Mahnaz Bayat Nasrin Jalali Maryam Poursadeghfard Mohammad Hossein Dabbaghmanesh Nahid Ashjazadeh |
| author_sort | Mahnaz Bayat |
| collection | DOAJ |
| description | Background: Medications can increase the incidence rate of metabolic syndrome (MetS) and insulin resistance (IR). This study aimed to evaluate the effects of Carbamazepine (CBZ) or Valproate (VPA) as monotherapy on the development of MetS and IR in adult Iranian epileptic patients.Methods: In this observational analytic case-control study, 80 epileptic patients were treated with VPA (40 patients) or CBZ (40 patients) monotherapies for more than 6 months, and 45 age- and sex-matched controls were included.Results: Subjects with MetS or with IR had higher age, weight, waist, FBS, cholesterol, systolic and diastolic pressure, TG, LDL, insulin, BMI, and lower HDL. In MetS and IR, the frequency of VPA or CBZ use was significantly higher than the control group. The multiple regression analysis showed that in VPA-treated epileptic patients, the risk of MetS was increased 19 times higher than controls (OR= 19.20; 95% CI= 2.62-140.23, P=0. 004) and risk of IR was increased 15 and 9 times more than controls (OR=14.83; 95% CI=3.03-72.56, P=0.001) and (OR=9.13; 95% CI=2.55-32.65, P= 0.001), respectively. An increase in the waist, DBP, and insulin level were also shown as important factors in the risk of MetS. In patients under CBZ therapy, the risk of MetS reduced by 17% less than controls and the risk of IR increased 7 times more than controls.Conclusion: Treatment with VPA may increase the likelihood of developing MetS and IR more than the CBZ therapy in epileptic patients in Iran. |
| first_indexed | 2024-03-13T02:09:39Z |
| format | Article |
| id | doaj.art-fb6829746f094418a88100ad397dd8ba |
| institution | Directory Open Access Journal |
| issn | 2008-2843 |
| language | English |
| last_indexed | 2024-03-13T02:09:39Z |
| publishDate | 2021-11-01 |
| publisher | Kerman University of Medical Sciences |
| record_format | Article |
| series | Journal of Kerman University of Medical Sciences |
| spelling | doaj.art-fb6829746f094418a88100ad397dd8ba2023-07-01T05:12:02ZengKerman University of Medical SciencesJournal of Kerman University of Medical Sciences2008-28432021-11-0128654855810.22062/jkmu.2021.9182691826Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control StudyMahnaz Bayat0Nasrin Jalali1Maryam Poursadeghfard2Mohammad Hossein Dabbaghmanesh3Nahid Ashjazadeh4Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, IranClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, IranClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran & Department of Neurology, Shiraz University of Medical Sciences, Shiraz, IranEndocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, IranDepartment of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran & Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, IranBackground: Medications can increase the incidence rate of metabolic syndrome (MetS) and insulin resistance (IR). This study aimed to evaluate the effects of Carbamazepine (CBZ) or Valproate (VPA) as monotherapy on the development of MetS and IR in adult Iranian epileptic patients.Methods: In this observational analytic case-control study, 80 epileptic patients were treated with VPA (40 patients) or CBZ (40 patients) monotherapies for more than 6 months, and 45 age- and sex-matched controls were included.Results: Subjects with MetS or with IR had higher age, weight, waist, FBS, cholesterol, systolic and diastolic pressure, TG, LDL, insulin, BMI, and lower HDL. In MetS and IR, the frequency of VPA or CBZ use was significantly higher than the control group. The multiple regression analysis showed that in VPA-treated epileptic patients, the risk of MetS was increased 19 times higher than controls (OR= 19.20; 95% CI= 2.62-140.23, P=0. 004) and risk of IR was increased 15 and 9 times more than controls (OR=14.83; 95% CI=3.03-72.56, P=0.001) and (OR=9.13; 95% CI=2.55-32.65, P= 0.001), respectively. An increase in the waist, DBP, and insulin level were also shown as important factors in the risk of MetS. In patients under CBZ therapy, the risk of MetS reduced by 17% less than controls and the risk of IR increased 7 times more than controls.Conclusion: Treatment with VPA may increase the likelihood of developing MetS and IR more than the CBZ therapy in epileptic patients in Iran.https://jkmu.kmu.ac.ir/article_91826_97358370ed05cb71b3acd1e6f8140296.pdfcholesterolcbz therapyvpa-treated patients |
| spellingShingle | Mahnaz Bayat Nasrin Jalali Maryam Poursadeghfard Mohammad Hossein Dabbaghmanesh Nahid Ashjazadeh Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study Journal of Kerman University of Medical Sciences cholesterol cbz therapy vpa-treated patients |
| title | Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study |
| title_full | Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study |
| title_fullStr | Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study |
| title_full_unstemmed | Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study |
| title_short | Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study |
| title_sort | metabolic syndrome and insulin resistance in sodium valproate or carbamazepine monotherapy a case control study |
| topic | cholesterol cbz therapy vpa-treated patients |
| url | https://jkmu.kmu.ac.ir/article_91826_97358370ed05cb71b3acd1e6f8140296.pdf |
| work_keys_str_mv | AT mahnazbayat metabolicsyndromeandinsulinresistanceinsodiumvalproateorcarbamazepinemonotherapyacasecontrolstudy AT nasrinjalali metabolicsyndromeandinsulinresistanceinsodiumvalproateorcarbamazepinemonotherapyacasecontrolstudy AT maryampoursadeghfard metabolicsyndromeandinsulinresistanceinsodiumvalproateorcarbamazepinemonotherapyacasecontrolstudy AT mohammadhosseindabbaghmanesh metabolicsyndromeandinsulinresistanceinsodiumvalproateorcarbamazepinemonotherapyacasecontrolstudy AT nahidashjazadeh metabolicsyndromeandinsulinresistanceinsodiumvalproateorcarbamazepinemonotherapyacasecontrolstudy |